Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.

Hiramatsu T, Asano Y, Mabuchi M, Imai K, Iguchi D, Furuta S

European journal of clinical investigation16 Aug 2018Cited by 23 (Europe PMC)

PMID30054920PMCIDPMC6175244DOI10.1111/eci.13007PepBankPUB-30054920

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, fasting glucose fell from baseline with liraglutide, as it did with sitagliptin and linagliptin.
In plain wordsIn adults with type 2 diabetes and kidney problems, fasting glucose fell from baseline with liraglutide and with the two comparison drugs.
Peptide
Liraglutide
Outcome
DecreaseFasting glucose
Study
n = 45
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, fasting glucose, postprandial glucose, and systolic and diastolic pressure, but not estimated glomerular filtration rate, significantly decreased in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492001
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, postprandial glucose fell from baseline with liraglutide, as it did with sitagliptin and linagliptin.
In plain wordsIn adults with type 2 diabetes and kidney problems, glucose after meals fell from baseline with liraglutide and with the two comparison drugs.
Peptide
Liraglutide
Outcome
DecreasePostprandial glucose
Study
n = 45
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, fasting glucose, postprandial glucose, and systolic and diastolic pressure, but not estimated glomerular filtration rate, significantly decreased in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492002
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, systolic pressure fell from baseline with liraglutide, as it did with sitagliptin and linagliptin.
In plain wordsIn adults with type 2 diabetes and kidney problems, systolic blood pressure fell from baseline with liraglutide and with the two comparison drugs.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n = 45
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, fasting glucose, postprandial glucose, and systolic and diastolic pressure, but not estimated glomerular filtration rate, significantly decreased in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492003
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, diastolic pressure fell from baseline with liraglutide, as it did with sitagliptin and linagliptin.
In plain wordsIn adults with type 2 diabetes and kidney problems, diastolic blood pressure fell from baseline with liraglutide and with the two comparison drugs.
Peptide
Liraglutide
Outcome
DecreaseDiastolic blood pressure
Study
n = 45
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, fasting glucose, postprandial glucose, and systolic and diastolic pressure, but not estimated glomerular filtration rate, significantly decreased in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492004
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, estimated glomerular filtration rate did not change significantly from baseline with liraglutide.
In plain wordsIn adults with type 2 diabetes and kidney problems, a measure of kidney filtering did not change significantly with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeEstimated glomerular filtration rate
Study
n = 45
Comparator
Baseline
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Compared with baseline, fasting glucose, postprandial glucose, and systolic and diastolic pressure, but not estimated glomerular filtration rate, significantly decreased in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492005
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, albuminuria decreased from 24 to 48 months with liraglutide, but only from 24 to 30 months with sitagliptin and linagliptin.
In plain wordsIn adults with type 2 diabetes and kidney problems, albumin in urine fell for longer with liraglutide than with sitagliptin or linagliptin.
Peptide
Liraglutide
Outcome
DecreaseAlbuminuria
Study
n = 45
Comparator
Sitagliptin and linagliptin
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Albuminuria decreased from 24 to 48 months with liraglutide, but only from 24 to 30 months with sitagliptin and linagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492006
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, diastolic function assessed by E/e' improved only with liraglutide, not with sitagliptin or linagliptin.
In plain wordsIn adults with type 2 diabetes and kidney problems, one heart relaxation measure improved with liraglutide but not with sitagliptin or linagliptin.
Peptide
Liraglutide
Outcome
Direction not reportedDiastolic function, E/e'
Study
n = 45
Comparator
Sitagliptin and linagliptin
Outcome group
Heart function · Cardiovascular
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Diastolic function, assessed by E/e' or left atrial dimension improved only with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492007
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and renal impairment, diastolic function assessed by left atrial dimension improved only with liraglutide, not with sitagliptin or linagliptin.
In plain wordsIn adults with type 2 diabetes and kidney problems, left atrial size improved with liraglutide but not with sitagliptin or linagliptin.
Peptide
Liraglutide
Outcome
Direction not reportedDiastolic function, left atrial dimension
Study
n = 45
Comparator
Sitagliptin and linagliptin
Outcome group
Heart function · Cardiovascular
Studied dose
0.9 mg/d · 48 monthsAs given in this study (human).
Source sentences
Summary
Diastolic function, assessed by E/e' or left atrial dimension improved only with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 139 patients who were referred because of suboptimal glycaemic control were randomly assigned to liraglutide 0.9 mg/d (n = 45), sitagliptin 50 mg/d, (n = 49) or linagliptin 5 mg/d (n = 45) at enrolment and were evaluated.
Report a problemFND-3005492008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms